Topical BPC-157 accelerated wound closure in alkali-burned rats by promoting granulation tissue formation, collagen deposition, and new blood vessel growth through the ERK1/2 signaling pathway.
Enhanced VEGF expression and vascular tube formationBPC-157 promoted new blood vessel growth in burn wounds through the ERK1/2 signaling pathway, providing a defined mechanism for its healing effects
What the researchers found
Topical BPC-157 accelerated wound closure in an alkali burn rat model compared to controls. By day 18 post-injury, treated wounds showed superior granulation tissue formation, reepithelialization, dermal remodeling, and collagen deposition on histological examination.
The mechanism was traced to angiogenesis (new blood vessel formation): BPC-157 increased VEGF expression in wounded skin, promoted proliferation and migration of human umbilical vein endothelial cells (HUVECs), and accelerated vascular tube formation in vitro. The ERK1/2 signaling pathway and its downstream targets (c-Fos, c-Jun, Egr-1) were identified as key mediators of these effects.
Why it matters
Chemical burns are common industrial and household injuries with limited treatment options. BPC-157's ability to promote both tissue regeneration and new blood vessel formation through a defined signaling pathway provides mechanistic support for its wound healing potential. Understanding the ERK1/2 mechanism also opens avenues for optimizing peptide-based wound therapies.
How the study worked
In vivo: Alkali burns were created on the skin of Sprague-Dawley rats, and BPC-157 was applied topically. Wound closure was monitored, and skin sections were examined histologically with H&E and Masson staining at day 18. In vitro: Human umbilical vein endothelial cells (HUVECs) were treated with BPC-157 and assessed for proliferation (MTT assay, cell cycle analysis), migration (Transwell and wound healing assays), VEGF expression, tube formation, and ERK1/2 pathway activation.
What this study cannot tell us
This is an animal study in rats — results may not translate directly to human chemical burns. The study doesn't report specific BPC-157 doses or concentrations used topically. Only one time point (day 18) was examined histologically, so the full healing trajectory is unclear. No human clinical trial data exists for BPC-157 in burn treatment.
How to read the evidence
This is a preclinical study combining an animal burn model with in vitro cell experiments. It provides strong mechanistic evidence but has not been validated in humans.
When this study was published
Published in 2015, this study remains frequently cited in BPC-157 research. The ERK1/2 mechanism it identified has been referenced in subsequent wound healing studies.
The bigger picture
BPC-157 has been studied extensively in animal models for tissue healing across multiple organ systems. This study adds mechanistic depth by identifying the ERK1/2-VEGF-angiogenesis axis as a key pathway. The topical application route is particularly relevant for clinical translation, as it avoids systemic exposure. However, like most BPC-157 research, human clinical trials remain absent.
Questions still open
- What concentration and frequency of topical BPC-157 application would be optimal for burn wounds?
- Would BPC-157 be effective for other types of burns (thermal, electrical) or only chemical burns?
- When will human clinical trials test topical BPC-157 for wound healing applications?
Common questions
What is BPC-157 and where does it come from?
How does BPC-157 help wounds heal?
Read the original research
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
Drug design, development and therapy, 9, 2485-99
Citation
Huang, Tonglie; Zhang, Kuo; Sun, Lijuan; Xue, Xiaochang; Zhang, Cun; Shu, Zhen; Mu, Nan; Gu, Jintao; Zhang, Wangqian; Wang, Yukun; Zhang, Yingqi; Zhang, Wei. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.. Drug design, development and therapy, 9, 2485-99. https://doi.org/10.2147/DDDT.S82030